US FDA not delivering on device user fee programme, says industry
This article was originally published in RAJ Devices
The US medtech industry has said that it will be hard-pressed to continue supporting the Food and Drug Administration's medical device user fee programme unless the agency demonstrates some improvement in delivering related quantitative and qualitative performance goals that will ensure the timely review of new medical devices being brought onto the market1.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.